FDA Approves First Drug for Friedreich’s Ataxia
Mar 1, 2023
The drug, omaveloxolone, is a once-a-day pill that will help improve neurological function and slow progression of the neurodegenerative disease.
Friedreich's Ataxia Program News
Our team of Friedreich's ataxia experts provides comprehensive care, from initial diagnosis and testing through long-term disease management.
Contact us
Friedreich’s Ataxia Center of Excellence at CHOP Awarded $1.275 Million to Advance Medical Research
Dec 10, 2020
The Friedreich’s Ataxia Center of Excellence at CHOP was awarded $1.275 million by the Friedreich’s Ataxia Research Alliance, Hamilton and Finneran families and the CureFA Foundation
In Pursuit of Cure for a Rare Degenerative Disease
Nov 8, 2017
A rare degenerative disease strikes during childhood. A multimillion-dollar gift is fueling CHOP scientists’ search for a cure.
$3.25 Million Gift Creates Friedreich’s Ataxia Center of Excellence
Mar 6, 2014
Donations from Friedreich’s Ataxia Research Alliance and the Hamilton and Finneran Families helps launch Penn Medicine/CHOP Center to improve research and care for Friedreich's Ataxia, a rare, degenerative disease.